Alcohol and Tobacco Consumption in Patients With Head and Neck or Lung Cancer
- Conditions
- Head and Neck CancerLung Cancer
- Interventions
- Behavioral: physician assessment
- Registration Number
- NCT01647425
- Lead Sponsor
- Centre Oscar Lambret
- Brief Summary
This is an multicenter study for preventive and therapeutic strategies for patients with head and neck cancer
- Detailed Description
Continuing the chronic intoxication by either tobacco or alcohol after the initial diagnosis of a first lung or head and neck cancer significantly improves the risk of experiencing a second cancer, and largely affects the long term survival. Addiction intervention programs should be personalized according to the patient's profile, with the aim to develop more sustained intervention and monitoring in patients identified at higher risk of not spontaneously stopping harmful substance use. As of today, the trajectories of smoking and drinking habits and the risk factors for persisting smoking or drinking habits have been insufficiently explored among patients with a first lung or head and neck cancer.
The ALTAK study aims to depict the rate of tobacco smokers 12 months after the initial diagnosis of a first lung or head and neck cancer. The secondary objectives of the study are:
* to depict the rate of alcohol users 12 months after the initial diagnosis of a H\&N cancer
* to depict the rate of tobacco smokers at cancer diagnosis
* to depict the rate of alcohol users at cancer diagnosis
* to determine the social, motivational, psychiatric, tobacco-related, alcohol-related, and cannabis-related features associated with stopping tobacco in the year following the diagnosis of a first TARC.
* to determine the social, psychiatric, tobacco-related, alcohol-related, and cannabis-related features associated with stopping alcohol drinking in the year following the diagnosis of a first H\&N cancer
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 385
- first head and neck or lung cancer
- first support
- age ≥ 18
- patient covered by health insurance
- signed informed consent
- prior lung or head and neck cancer
- History of another cancer <5 years, not evolutive and untreated at baseline (carcinoma of the cervix, or basal cell carcinoma of the skin properly treated are allowed). The presence of a second discovery tumor location at the same time as the lung or head and neck cancer, is not a criteria for non-inclusion
- mesothelioma and oesophageal cancer
- unable to undergo trail medical follow up (geographical, social and psychological reasons)
- pregnant or nursing women
- patient under guardianship
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description head and neck or lung cancer physician assessment patient with a first head and neck cancer or first lung cancer
- Primary Outcome Measures
Name Time Method tobacco consumption at 12 months reported tobacco smoking
- Secondary Outcome Measures
Name Time Method overall survival at 12 months median time between date of inclusion and date of death
tobacco smoking at baseline, 3 and 6 months frequency tobacco consumption
alcohol drinking at baseline, 3, 6 and 12 months frequency of alcohol consumption
progression free survival at 12 months median time between date of inclusion and date of first progression
sociodemographic, cancer-related, tobacco-related, alcohol-related, and psychiatric characteristics at baseline
Trial Locations
- Locations (3)
Oscar Lambret Center
🇫🇷Lille, France
Centre Hospitalier Régional et Universitaire - Hopital HURIEZ
🇫🇷Lille, France
Centre Hospitalier Régional et Universitaire - Hopital CALMETTE
🇫🇷Lille, France